<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="197904">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514449</url>
  </required_header>
  <id_info>
    <org_study_id>0602032</org_study_id>
    <nct_id>NCT00514449</nct_id>
  </id_info>
  <brief_title>Systematic Evaluation of Antiviral Medication in Schizophrenia</brief_title>
  <acronym>SEAMS</acronym>
  <official_title>A Randomized Double-blind Controlled Trial of Valacyclovir Add-on Treatment of HSV Positive Early Course Schizophrenia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether antiviral medication will help improve
      psychotic symptoms and cognition in individuals early in the course of schizophrenia or
      schizoaffective disorder who are exposed to herpes simplex virus, type 1 (HSV 1), a virus
      that causes commonly occurring and recurrent cold sores.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to evaluate the efficacy of add-on treatment of
      Valacyclovir (VAV), an antiviral medication, in the treatment of early course
      schizophrenia/schizoaffective disorder patients. Our main hypothesis is that the VAV add-on
      treatment will improve positive, negative and cognitive symptoms in herpes simplex virus
      (HSV) positive schizophrenia or schizoaffective disorder patients. We hypothesize that the
      grey matter reductions in specific brain regions (such as prefrontal regions) will improve
      in patients on VAV + antipsychotic compared to those on placebo + antipsychotic and the
      improvements in positive, negative and cognitive symptoms will be correlated with the grey
      matter changes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">February 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS Positive and Negative Syndrome Scale for schizophrenia</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 10, 14, 18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Function Neuropsychological Battery (Gur Battery)</measure>
    <time_frame>Baseline, Week 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Structural MRI (changes in grey matter deficits), fMRI (brain oxygenation level dependent, BOLD, responses)</measure>
    <time_frame>Baseline, Week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir + Antipsychotic</intervention_name>
    <description>1 g PO BID x 4 weeks after 4 weeks it goes up to 1.5 g PO BID x 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Antipsychotic</intervention_name>
    <description>2 pills twice a day x 4 weeks, after 4 weeks 3 pills twice a day x 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders between the ages of 18-50 years

          -  Schizophrenia or schizoaffective disorder as defined in DSM-IV

          -  Duration of illness 10 years or less

          -  On a stable dose of an antipsychotic medication for at least a month

          -  Should score 4 or more on at least one of the subscales of PANSS

          -  Positive for HSV1

          -  Written informed consent

        Exclusion Criteria:

          -  Substance abuse in the last month/dependence 6 months prior to the study

          -  History of, or current medical/neurological illnesses which affects CNS function
             e.g., epilepsy, head injury with prolonged loss of consciousness

          -  Pregnancy

          -  History of immune disorders, HIV infection or currently receiving immunosuppressants

          -  Subjects on regular antiviral therapy

          -  History of hypersensitivity to Valacyclovir

          -  Mental retardation as defined in DSM-IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konasale Prasad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Psychiatric Institute and Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Prasad KM, Shirts BH, Yolken RH, Keshavan MS, Nimgaonkar VL. Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. Mol Psychiatry. 2007 Jan;12(1):105-13, 1. Epub 2006 Oct 10.</citation>
    <PMID>17033628</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>February 17, 2011</lastchanged_date>
  <firstreceived_date>August 8, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Konasale Prasad, MD</name_title>
    <organization>Western Psychiatric Instititute and Clinic</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
